Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Glucagon-like peptide 1 receptor agonists (GLP-1) elicit substantial reductions in glycemia and body weight in people with type 2 diabetes (T2D) and obesity, but existing data suggest the therapy must be continued indefinitely to maintain clinical improvements. Given the high cost and poor real-world persistence of GLP-1, an effective therapy that enables deprescription with sustained clinical improvements would be beneficial. Thus, the purpose of this real-world study was to assess the effect of GLP-1 deprescription on glycemia and body weight following co-therapy with carbohydrate restricted nutrition therapy (CRNT) supported via telemedicine in a continuous remote care model. METHODS: A retrospective, propensity score matched cohort study among patients with T2D at a telemedicine clinic was conducted. Patients in whom GLP-1 were deprescribed (DeRx; n = 154) were matched 1:1 with patients in whom GLP-1 were continued (Rx). HbA1c and body weight at enrollment in clinic (pre-CRNT), at date of deprescription or index date (derx/ID), and at 6 and 12 months (m) post-derx/ID were utilized in this study. RESULTS: No regression in weight was observed following deprescription with > 70% maintaining ≥ 5% weight loss 12 m post-derx/ID. HbA1c rose 6 m and 12 m post-derx/ID in both DeRx and Rx cohorts, but most patients maintained HbA1c < 6.5%. HbA1c and body weight measured 6 m and 12 m following derx/ID did not significantly differ between cohorts and were improved at derx/ID and at follow-up intervals compared to pre-CRNT. CONCLUSION: These results demonstrate the potential for an alternate therapy, such as CRNT supported via telemedicine, to enable maintenance of weight loss and glycemia below therapeutic targets following discontinuation of GLP-1 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In another study,23 patients were maintained on a carbohydrate-restricted diet after cessation and experienced negligible weight regain.”
From Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression (2026) · cites this paper as [23]
In the citing paper
“Three studies22, 23, 24 reported little to no weight regain after substantial weight loss during treatment.”
From Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression (2026) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“Recent pharmaceutical advancements among incretin mimetics like GLP-1 show great potential, having elicited substantial glucose-lowering effects in T2D [9–16] and weight loss nearing that which is achieved through surgical intervention among people with excess weight or obesity without T2D [17, 18].”
BackgroundTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Recent pharmaceutical advancements among incretin mimetics like GLP-1 show great potential, having elicited substantial glucose-lowering effects in T2D [9–16] and weight loss nearing that which is achieved through surgical intervention among people with excess weight or obesity without T2D [17, 18].”
BackgroundEconomic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528 · cited 1×
“Prevalence of T2D, excess weight, and obesity continues to grow [3, 4] alongside the cost of healthcare for these conditions [5, 6], particularly through introduction of high cost medications associated with significant weight loss, such as glucagon-like peptide 1 receptor agonists (GLP-1) [7, 8].”
BackgroundRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“A similar regression in weight as well as fasting plasma glucose among individuals with T2D following the withdrawal of a GLP-1 drug was observed in the SCALE trial [23].”
BackgroundWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · cited 2×
“…months following deprescription of GLP-1 compared to a matched cohort in whom The STEP 1 trial extension showed rapid regression in glycemia and body weight following withdrawal of semaglutide administered in conjunction with a physical activity and caloric restriction lifestyle intervention [19].”
BackgroundResultRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · cited 1×
“Recent pharmaceutical advancements among incretin mimetics like GLP-1 show great potential, having elicited substantial glucose-lowering effects in T2D [9–16] and weight loss nearing that which is achieved through surgical intervention among people with excess weight or obesity without T2D [17, 18].”
BackgroundAronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 1×
“The STEP 4 and SURMOUNT 4 trials assessed withdrawal of GLP-1 therapy, but not lifestyle intervention, and showed regain of about half of the weight lost during combination therapy over the next 11–12 months while lifestyle intervention was continued [20, 24].”
Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
Iglay, K., Hannachi, H., Joseph Howie, P., Xu, J., Li, X., Engel, S. S., Moore, L. M., & Rajpathak, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1168291 · Cited by 511 · cited 1×
“About one in seven adults in the USA lives with type 2 diabetes (T2D) [1], and 78% also live with excess weight or obesity [2].”
BackgroundDirect medical costs of obesity in the United States and the most populous states
Cawley, J., Biener, A., Meyerhoefer, C., Ding, Y., Zvenyach, T., Smolarz, B. G., & Ramasamy, A. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.20410 · Cited by 400 · cited 1×
“Prevalence of T2D, excess weight, and obesity continues to grow [3, 4] alongside the cost of healthcare for these conditions [5, 6], particularly through introduction of high cost medications associated with significant weight loss, such as glucagon-like peptide 1 receptor agonists (GLP-1) [7, 8].”
BackgroundRelationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335 · cited 1×
“Carbohydrate restriction results in less glycemic variability [27], particularly post-meal—an effect similar to that which is achieved with GLP-1 therapy through delayed gastric emptying [28, 29].”
BackgroundAthinarayanan, S. J., Adams, R. N., Hallberg, S. J., McKenzie, A. L., Bhanpuri, N. H., Campbell, W. W., Volek, J. S., Phinney, S. D., & McCarter, J. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00348 · Cited by 324 · cited 1×
“…and sequential therapy to pharmaceuticals to enable eventual deprescription— particularly among interventions demonstrated to elicit significant weight loss, regression of prediabetes to normoglycemia, and remission of T2D, such as carbohydrate restricted nutrition therapy (CRNT) [21, 22].”
BackgroundSelf-citationEffect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · cited 1×
“Carbohydrate restriction results in less glycemic variability [27], particularly post-meal—an effect similar to that which is achieved with GLP-1 therapy through delayed gastric emptying [28, 29].”
BackgroundTay, J., Thompson, C. H., Luscombe‐Marsh, N. D., Wycherley, T. P., Noakes, M., Buckley, J. D., Wittert, G. A., Yancy, W. S., & Brinkworth, G. D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13164 · Cited by 215 · cited 1×
“Carbohydrate restriction results in less glycemic variability [27], particularly post-meal—an effect similar to that which is achieved with GLP-1 therapy through delayed gastric emptying [28, 29].”
BackgroundMcKenzie, A. L., Hallberg, S. J., Creighton, B. C., Volk, B. M., Link, T. M., Abner, M. K., Glon, R. M., McCarter, J. P., Volek, J. S., & Phinney, S. D. (2017) · JMIR Diabetes · doi:10.2196/diabetes.6981 · Cited by 176 · cited 1×
“…of the CRNT utilized in the present study reported reduced perceptions of hunger after 10 weeks of therapy concurrent with mean blood BHB of 0.6 mM [25], and blood BHB concentrations are associated with lower concentrations of the hunger hormone ghrelin and higher concentrations of satiety…”
MethodInfluentialSelf-citationWeiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152 · cited 1×
“For example, real-world persistence of GLP-1 therapy at 1 year is approximately 50% [36].”
BackgroundAthinarayanan, S. J., Hallberg, S. J., McKenzie, A. L., Lechner, K., King, S., McCarter, J. P., Volek, J. S., Phinney, S. D., & Krauss, R. M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01178-2 · Cited by 68 · cited 1×
“Past research has also shown that more frequent maintenance of nutritional ketosis is associated with improvements in atherogenic dyslipidemia, glycemia, body weight, and markers of renal function [30–32].”
BackgroundSelf-citationImpact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Patti, A. M., Rizvi, A. A., Giglio, R. V., Stoian, A. P., Ligi, D., & Mannello, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040912 · Cited by 59
Patti, A. M., Nikolic, D., Magan-Fernandez, A., Giglio, R. V., Castellino, G., Chianetta, R., Citarrella, R., Corrado, E., Provenzano, F., Provenzano, V., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.006 · Cited by 56
Novel Therapeutical Approaches to Managing Atherosclerotic Risk
Giglio, R. V., Pantea Stoian, A., Al-Rasadi, K., Banach, M., Patti, A. M., Ciaccio, M., Rizvi, A. A., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094633 · Cited by 54
Stoian, A. P., Sachinidis, A. G., Stoica, R. A., Nikolić, D., Patti, A. M., & Rizvi, A. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154295 · Cited by 48 · cited 1×
“Recent pharmaceutical advancements among incretin mimetics like GLP-1 show great potential, having elicited substantial glucose-lowering effects in T2D [9–16] and weight loss nearing that which is achieved through surgical intervention among people with excess weight or obesity without T2D [17, 18].”
BackgroundLingvay, I., Kirk, A. R., Lophaven, S., Wolden, M. L., & Shubrook, J. H. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01010-4 · Cited by 41
Nikolic, D., Patti, A. M., Giglio, R. V., Chianetta, R., Castellino, G., Magán-Fernández, A., Citarrella, R., Papanas, N., Janez, A., Stoian, A. P., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01217-z · Cited by 38
Type 2 Diabetes Prevention Focused on Normalization of Glycemia: A Two-Year Pilot Study
McKenzie, A. L., Athinarayanan, S. J., McCue, J. J., Adams, R. N., Keyes, M., McCarter, J. P., Volek, J. S., Phinney, S. D., & Hallberg, S. J. (2021) · Nutrients · doi:10.3390/nu13030749 · Cited by 37 · cited 1×
“…and sequential therapy to pharmaceuticals to enable eventual deprescription— particularly among interventions demonstrated to elicit significant weight loss, regression of prediabetes to normoglycemia, and remission of T2D, such as carbohydrate restricted nutrition therapy (CRNT) [21, 22].”
BackgroundSelf-citationRizzo, M., Nikolić, D., Banach, M., Giglio, R. V., Patti, A. M., Bartolo, V. D., Tamburello, A., Zabbara, A., Pecoraro, G., Montalto, G., et al. (2013) · Clinical Lipidology · doi:10.2217/clp.13.8 · Cited by 34
Powell, W., Song, X., Mohamed, Y., Walsh, D., Parks, E. J., McMahon, T. M., Khan, M., & Waitman, L. R. (2023) · Obesity · doi:10.1002/oby.23859 · Cited by 32 · cited 1×
“…than weight loss observed in STEP 2 among people with T2D treated with 2.4 mg and 1.0 mg semaglutide [10] and in the real world across 10 clinics [35], suggesting there may be benefit to pairing GLP-1 with CRNT therapy to achieve greater weight loss when clinically indicated or to enable greater…”
MethodInfluentialMartins, C., Nymo, S., Truby, H., Rehfeld, J. F., Hunter, G. R., & Gower, B. A. (2020) · Obesity · doi:10.1002/oby.23011 · Cited by 30 · cited 1×
“…reduced perceptions of hunger after 10 weeks of therapy concurrent with mean blood BHB of 0.6 mM [25], and blood BHB concentrations are associated with lower concentrations of the hunger hormone ghrelin and higher concentrations of satiety hormones glucagon-like peptide 1 and cholecystokinin [26].”
BackgroundInfluentialAthinarayanan, S. J., Adams, R. N., Hallberg, S. J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/476275 · Cited by 29
Self-citationChanges in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014–2019
Neilson, L. M., Munshi, K. D., Peasah, S. K., Huang, Y., Swart, E. C. S., Henderson, R. R., Manolis, C. H., & Good, C. B. (2021) · Medical Care · doi:10.1097/mlr.0000000000001597 · Cited by 17 · cited 1×
“Prevalence of T2D, excess weight, and obesity continues to grow [3, 4] alongside the cost of healthcare for these conditions [5, 6], particularly through introduction of high cost medications associated with significant weight loss, such as glucagon-like peptide 1 receptor agonists (GLP-1) [7, 8].”
BackgroundAmbulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019
Heyward, J., Christopher, J., Sarkar, S., Shin, J., Kalyani, R. R., & Alexander, G. C. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14408 · Cited by 16 · cited 1×
“Prevalence of T2D, excess weight, and obesity continues to grow [3, 4] alongside the cost of healthcare for these conditions [5, 6], particularly through introduction of high cost medications associated with significant weight loss, such as glucagon-like peptide 1 receptor agonists (GLP-1) [7, 8].”
BackgroundCrabtree, T. S. J., Adamson, K., Reid, H., Barnes, D., Sivappriyan, S., Bickerton, A., Gallen, I. W., Field, B. C. T., Idris, I., Ryder, R. E. J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14701 · Cited by 14 · cited 1×
“Further improvement in glycemia and weight elicited with this combination therapy exceeds effects observed in other real-world studies among those who switched to injectable semaglutide from less potent GLP-1 [33, 34].”
ResultAthinarayanan, S. J., Roberts, C. G. P., Adams, R. N., Volk, B. M., Phinney, S. D., VOLEK, J., & McKenzie, A. L. (2023) · Diabetes · doi:10.2337/db23-410-p · Cited by 9 · cited 1×
“Past research has also shown that more frequent maintenance of nutritional ketosis is associated with improvements in atherogenic dyslipidemia, glycemia, body weight, and markers of renal function [30–32].”
BackgroundSelf-citationMcKenzie, A. L., Athinarayanan, S. J., Roberts, C. G. P., Adams, R. N., Volk, B. M., Phinney, S. D., & VOLEK, J. (2023) · Diabetes · doi:10.2337/db23-312-or · Cited by 1
Self-citation
Cited by
Budini, B., Luo, S., Tam, M., Stead, I., Lee, A., Akrami, A., Vidal-Puig, A., & Park, A. (2026) · eClinicalMedicine · doi:10.1016/j.eclinm.2026.103796 · Cited by 52
“Data analysis and visualisation were conducted us-ing R (version 4.3.2) with the nlme and ggplot2 packages.”
InfluentialVolek, J. S., Kackley, M. L., & Buga, A. (2024) · Current Nutrition Reports · doi:10.1007/s13668-024-00548-6 · Cited by 48
“On a more promising note, the results of clinical trials indicate that bariatric surgery [6], very low-carbohydrate ketogenic diets [7, 8], and the recently developed GLP1 receptor agonists [9] have the most potent ability to produce substantial weight loss, but all requite proper attention to diet…”
BackgroundResultRosenfeld, R. M., Grega, M. L., Karlsen, M. C., Dabrh, A. M. A., Aurora, R. N., Bonnet, J. P., Donnell, L., Fitzpatrick, S. L., Frates, E. P., Joy, E. A., et al. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251325488 · Cited by 54
Buchanan, L., Calkins, M. W., Kalayjian, T., Norwitz, N. G., Teicholz, N., Unwin, D., & Soto-Mota, A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1548609 · Cited by 12
The ketogenic diet is not for everyone: contraindications, side effects, and drug interactions
Dyńka, D., Rodzeń, Ł., Rodzeń, M., Łojko, D., Karakuła‐Juchnowicz, H., Ede, G., Grzywacz, Ż., Antosik, K., Sethi, S., & Unwin, D. (2026) · Annals of Medicine · doi:10.1080/07853890.2025.2603016 · Cited by 16
“In fact, it is known that GLP-1 analogues may be associated with hypoglycaemia [286], which should be kept in mind when combining with the KD. Low-carbohydrate diets have been shown to help patients maintain glycaemic and weight control even after discontinuing these drugs [287,288].”
Metadata
- Authors
- McKenzie, A. L., & Athinarayanan, S. J.
- Corresponding author
- Athinarayanan, Shaminie J.
- Venue
- Diabetes Therapy
- Published
- 2024-02-29
- Volume
- 15
- Issue
- 4
- Pages
- 843-853
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC10951146
- OpenAlex
- W4392289233
- Cited by
- 14
- References
- 33
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 4
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, deprescribing, type 2 diabetes, telemedicine, glycemic control, HbA1c, weight loss maintenance, remote care, drug discontinuation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.